You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Dow
Boehringer Ingelheim
Colorcon
AstraZeneca

Last Updated: May 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Entinostat


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Entinostat?

Entinostat is an investigational drug.

There have been 63 clinical trials for Entinostat. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Syndax Pharmaceuticals, National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.

There are one hundred and forty-seven US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Entinostat
TitleSponsorPhase
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)National Cancer Institute (NCI)Phase 1
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerUNC Lineberger Comprehensive Cancer CenterPhase 2
Molibresib and Entinostat in Treating Patients With Advanced or Refractory Solid Tumors or LymphomasNational Cancer Institute (NCI)Phase 1

See all Entinostat clinical trials

Clinical Trial Summary for Entinostat

Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat

See all Entinostat clinical trials

US Patents for Entinostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Entinostat   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Entinostat   Start Trial Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III Frequency Therapeutics, Inc. (Woburn, MA)   Start Trial
Entinostat   Start Trial Liposomal compositions of epoxyketone-based proteasome inhibitors Onyx Therapeutics, Inc. (Thousand Oaks, CA)   Start Trial
Entinostat   Start Trial Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Lixte Biotechnology, Inc. (East Setauket, NY)   Start Trial
Entinostat   Start Trial Substituted 6-aminopurines for targeting HSP90 Duke University (Durham, NC)   Start Trial
Entinostat   Start Trial Cyclodextrin complexation methods for formulating peptide proteasome inhibitors Onyx Therapeutics, Inc. (Thousand Oaks, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Entinostat

Drugname Country Document Number Estimated Expiration Related US Patent
Entinostat World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Entinostat Australia 2013292636 2032-07-18   Start Trial
Entinostat Australia 2013292647 2032-07-18   Start Trial
Entinostat Australia 2018201445 2032-07-18   Start Trial
Entinostat Canada 2879139 2032-07-18   Start Trial
Entinostat Canada 2879208 2032-07-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Dow
McKesson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.